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ABSTRACT
RNA editing is a post-transcriptional modification of
pre-mRNA that results in increased diversity in
transcriptomes and proteomes. It occurs in a wide
variety of eukaryotic organisms and in some
viruses. One of the most common forms of
pre-mRNA editing is A-to-I editing, in which
adenosine is deaminated to inosine, which is read
as guanosine during translation. This phenomenon
has been observed in numerous transcripts,
including the mammalian 5-HT2C receptor, which
can be edited at five distinct sites. Methods used to
date to quantify 5-HT2C receptor editing are
labor-intensive, expensive and provide limited infor-
mation regarding the relative abundance of 5-HT2C
receptor editing variants. Here, we present a novel,
ultra high-throughput method to quantify 5-HT2C
receptor editing, compare it to a more conventional
method, and use it to assess the effect of a range of
genetic and pharmacologic manipulations on 5-HT2C
editing. We conclude that this new method is
powerful and economical, and we provide evidence
thatalterationsin5-HT2Ceditingappeartobearesult
of regional changes in brain activity, rather than a
mechanism to normalize 5-HT2C signaling.
INTRODUCTION
The post-transcriptional modiﬁcation of RNA, or RNA
editing, was ﬁrst reported in trypanosome mitochondria
(1). De-amination of adenosine to inosine, the most
common type of RNA editing in higher eukaryotes (2),
was ﬁrst demonstrated in mammals at murine glutamate
receptor subunit transcripts (3) and has been reported in
organisms ranging from fruit ﬂies to rodents and humans,
and a number of instances have been reported in viruses
(4). A family of enzymes referred to as Adenosine
Deaminases that Act on RNA (ADAR) performs the
deaminations, which underlie this type of RNA editing
(2). It has been shown that the genetic deletion of all
ADAR activity in Drosophila severely impairs central
nervous system (CNS) function and integrity (5). A-to-I
editing has been shown to be critical for normal
embryogenesis in mammals, since genetic deletion of
ADAR1 in mice is embryonically lethal (6). Genetic
deletion of ADAR2 in mice, on the other hand, increases
seizure susceptibility and decreases post-natal survival
(7). The inosine content of transcripts isolated from dif-
ferent tissues suggests that the known edited transcripts
only account for a small fraction of the editing that is
likely to take place, that RNA editing takes place
predominantly in non-coding regions of RNA transcripts
containing inverted repetitive elements of the Alu and L1
subclass, and that RNA editing is most common in the
brain (8–13).
The 5-hydroxytryptamine-2C (5-HT2C; HTR2C)
serotonin receptor is the only G protein-coupled
receptor (GPCR), whose transcripts have been shown to
undergo RNA editing. RNA editing of 5-HT2C transcripts
takes place at one or more of ﬁve closely spaced
adenosines in a region that codes for a portion of the sec-
ond intracellular loop of the receptor (14,15). ADAR1
has been shown to be primarily responsible for editing
the two 50 sites, while ADAR2 edits the two 30 sites (16).
RNA editing has been shown to reduce the eﬃciency of
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in vivo studies suggest that the altered signaling properties
of 5-HT2C isoforms that result from RNA editing can lead
to physiological consequences, as mutant mice expressing
only the fully edited VGV isoform are characterized by
signiﬁcant abnormalities in receptor expression, feeding,
and metabolism (18).
5-HT2C RNA editing abnormalities have been reported
in the brains of suicide victims with a history of major
depression, whereas treatment with the antidepressant
drug ﬂuoxetine induces changes in the opposite direction
in mice (19). Other studies have suggested that 5-HT2C
editing is decreased in the frontal cortex of schizophrenia
patients (20), and serotonin depletion by parachlorophe-
nylalanine (pCPA) induces alterations similar to those
seen after ﬂuoxetine treatment (21). Indeed, a number of
studies have suggested changes in editing after treatment
with medications that target serotonin receptors or alter
serotonin levels, but the results have been both inconsis-
tent and diﬃcult to replicate (15,22). Furthermore, it is
diﬃcult to reconcile any mechanistic hypothesis with
the observed changes, given the known activities and
speciﬁcities of ADAR1 and ADAR2.
Several methods have been developed to facilitate mea-
surement of RNA editing at the 5-HT2C receptor and other
edited pre-mRNAs. One commonly used and informative
method is to individually sequence large numbers of tran-
scripts (anywhere from 20 to 100 or more) (14,23,24). This
individual sequencing approach is both labor intensive and
inadequate for quantifying the levels of rare transcripts.
Other methods include primer extension assays (25) and
pyrosequencing (26), which are quantitative and provide
information about editing frequencies at each site, but give
insuﬃcient or no information regarding the frequencies of
the diﬀerent transcripts/isoforms. We have adapted a
newly developed ultra high-throughput sequencing (HTS)
technology, the Illumina Genome Analyzer II, to quantify
5-HT2C pre-mRNA editing. This approach is several
orders of magnitude less expensive on a per transcript
basis, and provides more comprehensive and quantitative
information regarding RNA editing events. We compare
our HTS-based method to the most commonly used indi-
vidual sequencing method and assess the eﬀect of a range
of genetic manipulations and pharmacologic treatments on
5-HT2C editing.
MATERIALS AND METHODS
Mice
A detailed description of how the Pet-1 mice were
generated has been reported previously (27). C57BL/6
mice were purchased from Jackson Laboratories.
C57BL/6 mice were injected with either saline or drug
daily for 10, 14 or 28 days and sacriﬁced on the
last day of injections. Diﬀerent brain regions were then
microdissected and frozen at  80 C until use. Treatment
dose and length were based on literature reports of drug
regimens that resulted in measurable eﬀects at the bio-
chemical and/or behavioral level (see the relevant
‘Results’ section for the individual citations). All
experiments were approved by the Institutional Animal
Care and Use Committee at Case Western Reserve
University or the University of North Carolina, Chapel
Hill. Mice were housed under standard conditions—12h
light/dark cycle and food and water ad libitum.
Generation of cDNA from RNA
Trizol (Invitrogen) was used to extract RNA from
microdissected hippocampal tissue. Ten mg of RNA was
treated with DNAse (DNA-free, Ambion), and 2mg of the
DNase-treated RNA was added to a reverse transcription
reaction which was performed using the Superscript
TM III
RNase H Reverse Transcriptase kit (Invitrogen) with
Oligo-(dT)12–18 primers (Invitrogen). cDNA was used as
template to generate a double-stranded DNA fragment by
PCR for both the low-throughput sequencing (LTS) and
high-throughput sequencing (HTS) experiments.
LTS
A PCR fragment (containing the edited site) that was
327bp in length was generated for each of three Pet-1
wild-type and three Pet-1 knockout animals (Forward
primer: 50 AAA GGATCC TGT GCT ATT TTC AAC
TGC GTC CAT CAT G 30; Reverse primer: 50 AAA GAA
TTC CGG CGT AGG ACG TAG ATC GTTAAG 30)
(24). The PCR DNA concentrations were determined, and
the DNA from the three animals of each genotype was
mixed in equal amounts and inserted into the BamHI/
EcoRI sites of pcDNA3 (Rapid DNA ligation kit,
Roche). The ligation product was transformed into
bacteria and plated; each clone represents an individual
transcript, and the clones were assumed to be evenly
distributed in origin between the three animals used
for each ligation since equal amounts of DNA were used
from each in the ligation reaction. Clones were
miniprepped using the Wizard Plus SV Miniprep kit
(Promega), and they were sequenced by Sanger sequencing
to assess 5-HT2C RNA editing. Seventy-eight wild-
type transcripts and 88 knockout transcripts were
sequenced.
Ultra HTS
5-HT2C editing in Pet-1 mice. One microliter of cDNA
(of 20ml) was used as template for a 50ml PCR reaction
(conditions: 1 cycle—95 C, 2min; 30 cycles—95 C3 0 s ,
52 C3 0 s ,7 2  C 1min; 1 cycle—72 C 10min) to amplify
a fragment (lowercase letters for the portions of the
primers complementary to 5-HT2C sequence) containing
the edited region of interest using Pfu turbo polymerase
(Stratagene). The primers used also contained adapter
sequences (uppercase letters in bold) necessary for
cluster generation:
Forward primer: AATGATACGGCGACCACCGAGAT
CTACACTgcgccatatcgctggaccggtat;
Reverse primer: CAAGCAGAAGACGGCATACGAGAT
gccacgaaggacccgatgagaacg
PCR fragments (283bp in length) were gel puriﬁed
using the QIAquick gel extraction kit, and 1ml was used
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round of PCR is typically unnecessary since <100ng of
DNA is needed from each experiment using fragments of
this size.
5-HT2C editing in chronic saline and drug-treated C57BL/6
mice. Performed as described above, except the round one
PCR reaction was 20ml. Additionally, the forward primer
contained a sequence corresponding to a sequencing
primer optimized by Illumina for use with the Genome
Analyzer II (non-bolded uppercase letters), as well as a
sample identiﬁcation tag, which was a random nucleotide
sequence 5–10 nucleotides in length (underlined uppercase
letters, with ‘AAAAA’ being the tag for sample one and
the other 25 tags as follows: ATCAT, GGGGG, TTTTT,
AAGGT, GGTAT, AATTG, AGTGA, TTGGA, TTAA
G, GTGTA, ATATG, ATCAT ATCAT, AAAAA AAA
AA, GGGGG GGGGG, TTTTT TTTTT, AAGGT AA
GGT, GGTAT GGTAT, AATTG AATTG, AGTGA A
GTGA, TTGGA TTGGA, TTAAG TTAAG, GTGTA G
TGTA, ATATG ATATG, AAAAA GGGGG, GGGGG
AAAAA). As before, the bolded, italic portions of the
primers represent adapter sequence, and the lower case
portions represent sequence complementary to 5-HT2C
pre-mRNA sequence. Each sample used a diﬀerent
forward primer (26 diﬀerent forward primers total) con-
taining a diﬀerent identiﬁcation tag, with the rest of the
primer being identical. All reactions used the same reverse
primer.
Forward primer:
AATGATACGGCGACCACCGAGATCTACACTACA
CTCTTTCCCTACACGACGCTCTTCCGATCTAAA
AAtcgctggaccggtatgtagc
Reverse primer:
CAAGCAGAAGACGGCATACGAGATcgtccctcagtccaa
tcacagg
One microliter of PCR reaction one was used as
template for another round of PCR, the volume of these
reactions being 50ml each, and the 257-bp fragment from
this second round of PCR was gel puriﬁed using the
MinElute PCR Puriﬁcation kit (Qiagen). A portion of
the gel-puriﬁed PCR DNA from each sample was used
for gel quantiﬁcation, and 24–26 samples were mixed in
equal parts for HTS.
Gel puriﬁed PCR DNA was diluted to a concentration
of 15nM. Two microliters was used for denaturation
(total volume 20ml). 4ml of the denaturation mixture
was diluted in 996ml of hybridization solution. The
hybridization mixture (ﬁnal DNA concentration about
6 pM) was loaded into the Cluster Station for cluster gen-
eration. Primer hybridization was performed on the
Cluster Station using 6.6ml of 500nM sequencing primer
(PET-1 experiment primer sequence: gcgccatatcgctg-
gaccggtat; multiplexed experiment primer sequence:
acactctttccctacacgacgctcttccgatct) diluted in 1313mlo f
hybridization buﬀer. Cluster generation was performed
for 36 cycles (Pet-1 experiment) or 76 cycles (ﬂuoxetine
experiment), followed by base-by-base sequencing
initiated by the sequencing primer on the Genome
Analyzer II. The Genome Analyzer II uses two
diﬀerent lasers to excite the dye attached to each
nucleotide. Since the emission spectra of these four dyes
overlap, the four images thus obtained are not indepen-
dent. As in Sanger sequencing, the frequency cross-talk is
deconvolved using a frequency cross-talk matrix.
Therefore, the crosstalk matrix calculation requires
control lanes for samples with skewed base compositions.
Thus, a control human genomic DNA sample was run in
parallel on the same ﬂow-cell concurrently with 5-HT2C
editing samples. Any non-skewed DNA library can be
used for this purpose. For the Pet-1 experiment, sequences
that passed all three of our quality ﬁlters were sorted and
counted using Textpad. MySQL 4.0, an open source and
multi-platform relational database management system,
was used to sort and count transcript reads that passed
the ﬁrst ﬁlter, which permitted comparison of ‘false’ tran-
script counts to theoretically real transcript counts. For
the multiplexed experiment, sequences were analyzed
using a Perl 5 script (available at http://pdsp-temp
.pha-med.unc.edu/Download/code.php) written by us to
ﬁlter the data through three quality ﬁlters and sort the
data which passed the ﬁlters. Further data analysis was
performed in Microsoft Excel and Graphpad Prism 5.0.
All statistical analyses were performed in Graphpad Prism
5.0. N=3 littermate pairs for the samples used to measure
hippocampal 5-HT2C RNA editing in Pet-1 wildtype and
knockout mice, whereas N=4 for the multiplexed exper-
iment. For the purposes of making statistical compari-
sons, all the reads generated from one animal in the
HTS studies were together treated as one experiment
(N=3–4 for each genotype). For the LTS analysis, each
read was treated as an experiment (N=78 for WT,
N=88 for KO).
RESULTS
Processing transcript reads obtained by ultra HTS
In order to explore the potential of ultra HTS methods for
assessing 5-HT2C transcript editing frequencies, we
measured RNA editing in hippocampi from Pet-1
wild-type and knockout mice. The hippocampus was
chosen because it is the region with the highest expression
of neuronal 5-HT2C receptor mRNA (28). Pet-1 is an ETS
domain transcription factor that is necessary for the
normal development of serotonergic neurons (27), and
Pet-1 knockout mice have very low levels of brain
serotonin. We also compared two methods for measuring
RNA editing and transcript/isoform frequencies:
sequencing individual transcripts by Sanger sequencing
versus ultra HTS using reversible terminator chemistry
(29,30) with the Illumina Genome Analyzer II platform.
The 5-HT2C receptor is A-to-I edited at varying
frequencies at one or more of ﬁve sites: A, B, C, D and
E (Figure 1A). Adenosines deaminated to inosine are read
as guanosines when 5-HT2C RNA is reverse-transcribed,
PCR-ampliﬁed and sequenced. Since the Genome
Analyzer II-based ultra HTS read length is 36bp, the
sequencing primer was designed such that it provided
reads beginning at the  5 position relative to the ﬁrst
edited site (Table 1). We analyzed three samples from
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raw sequence reads for the six mice. All sequences were
subsequently processed through three sets of ‘quality’
ﬁlters intended to retain only those sequences
which appeared to provide error-free, reliable reads
(Figure 1B). All quality ﬁlters are an application of a strin-
gent binary DNA sequence quality criterion: reads would
be divided into two groups, those containing one or more
detectable sequencing errors, and those containing no
detectable sequencing errors. Only those with no detect-
able errors would be used for transcript quantiﬁcation,
though it should be noted that our analysis indicated
that less stringent ﬁltering (for example, by using a
shorter initial proofreading ﬁlter) did not change results
signiﬁcantly (data not shown). For the ﬁrst quality ﬁlter,
we used the ﬁve non-edited positions preceding the ﬁrst
edited (‘A’) site and the 17 non-edited positions down-
stream from the last edited (‘D’) site to ﬁlter the initial
pool of sequences. All reads containing errors in any of
the aforementioned 22 sites were removed from the
analysis (13790980 sequences). The remaining reads
(8861462 sequences) were then passed through two addi-
tional ﬁlters, which removed all transcripts containing a
sequencing error in any of the eight non-edited sites within
the region of interest spanning the A to D sites and/or
contained a cytosine or a thymine at one of the edited
sites (213997 sequences). Sequences that failed these last
two ﬁlters were binned by read and the number of reads in
each bin was counted. Interestingly, some of these ‘false
transcripts’ occurred at higher frequencies than a number
of the rarer transcripts that passed all the ﬁlters. Notably,
the same false transcripts recurred at high frequency in all
the samples examined, and they typically diﬀered from
one of the most common transcripts by one base, suggest-
ing that they resulted from misreads of common tran-
scripts. The remaining sequences that passed all three
‘quality ﬁlters’ were sorted into 32 bins, one for each the-
oretically possible transcript (Table 1), and the number of
sequence reads in each of these bins was then counted.
Calculating transcript frequency thresholds
The recurrence of the same false transcripts in each
sample, some at frequencies higher than theoretically
possible transcripts, suggested the possibility that the
reads of some of the rarer transcripts may have arisen
largely due to A-to-G or G-to-A misreads of more
common transcripts. Since it was impossible to determine
a priori whether or not this was the case, we ﬁrst under-
took a detailed analysis of the error rates at the ﬁrst
three adenines and guanines in non-edited region 2
(Figure 1B). Noting that adenines and guanines were
most commonly misread as cytosine, and least
commonly as thymine, we calculated the A-to-G and
G-to-A error rates at each site for each animal and
averaged all three sites, since the rates at the diﬀerent
sites were not signiﬁcantly diﬀerent from each other,
and they did not depend on the genotype of the samples
(Table 2 and data not shown). We reasoned that each
transcript read could have arisen from an A-to-G or
G-to-A misread at any one of the ﬁve edited sites,
meaning, in other words, that each transcript is separated
from ﬁve other transcripts by a single base pair diﬀerence.
By multiplying our calculated error rates by the
frequencies of the occurrence of the ﬁve closely related
transcripts and summing the ﬁve resulting values, we
were able to estimate the proportion of the reads of a
given transcript that were likely to have arisen due to
misreads of other transcripts (Table 3). Our calculations
indicated that the majority of transcript reads, in every
instance, do not result from sequencing error, even
in the cases of the rarest transcripts, which were seen
at lower frequency than the most common false tran-
scripts. In fact, our calculated estimates of the expected
frequencies of occurrence of the most common false
transcripts were consistent with what was seen experi-
mentally (data not shown), suggesting that our calculated
thresholds were reasonable. Thus, we considered all of
the transcripts to have occurred at rates above our
detection threshold, though some appear to be extremely
rare.
Figure 1. Schematic of the ultra HTS strategy used to measure RNA
editing. (A) A representative full-sequence read with the ﬁve edited sites
labeled. Guanosines at edited sites correspond to inosines in the
original RNA transcript from which the sequenced DNA is derived.
(B) Ultra HTS sequencing produced 22652442/122828564 sequences.
Non-edited region 1 and non-edited region 2 were used to ﬁlter
sequences with misreads in those regions (13790980 sequences).
Non-edited regions 3, 4 and 5 were then used to ﬁlter the remaining
8861462/92958400 sequences in a similar fashion to remove the
sequences containing misreads in those regions, and theoretically
impossible transcripts (in other words, those with a C or T at an
edited site) were also ﬁltered (213997/21770405 sequences failed after
applying the last two ﬁlters), leaving 8647465/71187995 sequences
used for subsequent analysis.
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In parallel with our ultra HTS experiment, we also
measured 5-HT2C RNA editing by the most common
LTS approach to provide a realistic comparison of
ﬁndings (24). First, we compared both methods with
respect to their ability to detect all 32 possible
transcripts (Table 4). Not surprisingly, HTS was able to
detect all transcripts in both Pet-1 wild-type and knockout
mice, whereas LTS detected only 20 of 32 possible
transcripts, with 12 of those 20 detected in only one
or the other genotype. Our LTS results are consis-
tent with many previous studies in being able to detect
only a subset of all theoretically possible transcripts
(15). Thus, HTS appears to be superior to LTS with
respect to the ability to comprehensively detect all
transcripts.
Comparison of the overall editing frequencies at each of
the ﬁve sites indicates that HTS and LTS report similar
editing frequencies (Figure 2). Two-way ANOVA analysis
with Bonferonni post-tests to compare LTS and HTS
results indicates that, where comparison is possible (with
the more common transcripts), there are no signiﬁcant
diﬀerences in the estimates obtained by the two
methods. Thus, we validated both the method and the
subsequent ﬁlters applied to the data. Two-way ANOVA
analysis indicates that genotype has no eﬀect on
editing frequency variation (HTS P-value=0.4369; LTS
P-value=0.0812). Bonferroni post-tests to perform
pairwise comparisons of genotype eﬀect conﬁrmed that
there is no signiﬁcant between-genotype diﬀerence
in editing frequencies measured by the two methods
(Figure 2A). Furthermore, two-way ANOVA analysis
Table 1. Complete transcript reads
Isoform Transcript Complete read
INI AAAAA TAGCAATACGTAATCCTATTGAGCATAGCCGGTTC
INV AAAAG TAGCAATACGTAATCCTGTTGAGCATAGCCGGTTC
ISI AAAGA TAGCAATACGTAGTCCTATTGAGCATAGCCGGTTC
ISV AAAGG TAGCAATACGTAGTCCTGTTGAGCATAGCCGGTTC
IDI AAGAA TAGCAATACGTGATCCTATTGAGCATAGCCGGTTC
IDV AAGAG TAGCAATACGTGATCCTGTTGAGCATAGCCGGTTC
IGI AAGGA TAGCAATACGTGGTCCTATTGAGCATAGCCGGTTC
IGV AAGGG TAGCAATACGTGGTCCTGTTGAGCATAGCCGGTTC
MNI AGAAA TAGCAATGCGTAATCCTATTGAGCATAGCCGGTTC
MNV AGAAG TAGCAATGCGTAATCCTGTTGAGCATAGCCGGTTC
MSI AGAGA TAGCAATGCGTAGTCCTATTGAGCATAGCCGGTTC
MSV AGAGG TAGCAATGCGTAGTCCTGTTGAGCATAGCCGGTTC
MDI AGGAA TAGCAATGCGTGATCCTATTGAGCATAGCCGGTTC
MDV AGGAG TAGCAATGCGTGATCCTGTTGAGCATAGCCGGTTC
MGI AGGGA TAGCAATGCGTGGTCCTATTGAGCATAGCCGGTTC
MGV AGGGG TAGCAATGCGTGGTCCTGTTGAGCATAGCCGGTTC
VDI GGGAA TAGCAGTGCGTGATCCTATTGAGCATAGCCGGTTC
VDV GGGAG TAGCAGTGCGTGATCCTGTTGAGCATAGCCGGTTC
VGI GGGGA TAGCAGTGCGTGGTCCTATTGAGCATAGCCGGTTC
VGV GGGGG TAGCAGTGCGTGGTCCTGTTGAGCATAGCCGGTTC
VNI GGAAA TAGCAGTGCGTAATCCTATTGAGCATAGCCGGTTC
VNV GGAAG TAGCAGTGCGTAATCCTGTTGAGCATAGCCGGTTC
VSI GGAGA TAGCAGTGCGTAGTCCTATTGAGCATAGCCGGTTC
VSV GGAGG TAGCAGTGCGTAGTCCTGTTGAGCATAGCCGGTTC
VDI GAGAA TAGCAGTACGTGATCCTATTGAGCATAGCCGGTTC
VDV GAGAG TAGCAGTACGTGATCCTGTTGAGCATAGCCGGTTC
VGI GAGGA TAGCAGTACGTGGTCCTATTGAGCATAGCCGGTTC
VGV GAGGG TAGCAGTACGTGGTCCTGTTGAGCATAGCCGGTTC
VNI GAAAA TAGCAGTACGTAATCCTATTGAGCATAGCCGGTTC
VNV GAAAG TAGCAGTACGTAATCCTGTTGAGCATAGCCGGTTC
VSI GAAGA TAGCAGTACGTAGTCCTATTGAGCATAGCCGGTTC
VSV GAAGG TAGCAGTACGTAGTCCTGTTGAGCATAGCCGGTTC
Table 2. Estimate of A-to-G and G-to-A Error Rates (%)
Site WT1 WT2 WT3 KO1 KO2 KO3 AVG
Average A-to-G error rate
Site 1 TTGAGCATAGCCGGTT 0.08 0.07 0.08 0.07 0.07 0.05
Site 2 TTGAGCATAGCCGGTT 0.05 0.06 0.05 0.05 0.05 0.04 0.05
Site 3 TTGAGCATAGCCGGTT 0.04 0.05 0.04 0.05 0.04 0.04
Average G-to-A error rate
Site 1 TTGAGCATAGCCGGTT 0.05 0.04 0.04 0.04 0.05 0.05
Site 2 TTGAGCATAGCCGGTT 0.06 0.05 0.04 0.05 0.05 0.05 0.04
Site 3 TTGAGCATAGCCGGTT 0.03 0.04 0.04 0.03 0.05 0.04
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paring common transcripts detected in both genotypes
with both methods shows no signiﬁcant eﬀect of
genotype on common transcript frequency diﬀerences,
and Bonferroni post-tests conﬁrm no signiﬁcant eﬀect
of genotype on transcript frequencies (Figure 2B).
Additionally, we would point out that HTS produces tran-
script frequency estimates that range over approximately
ﬁve orders of magnitude, in contrast to LTS, where the
estimates range over one order of magnitude. Not
surprisingly, in measuring the frequencies of rare tran-
scripts, HTS is clearly superior to LTS (Figure 2C).
HTS allows statistical comparison between wildtype and
knockout animals with all 23 rare transcripts in question.
LTS, in contrast, does not detect any one of the 23 rare
transcripts in both wild-type and knockout animals,
making any statistical comparison for the rare transcripts
impossible. Two-way ANOVA analysis of the HTS data
shows no eﬀect of genotype on transcript frequency
(P=0.9867), which is conﬁrmed by Bonferroni post-tests.
Multiplexing HTS technology to simplify the
measurement of 5-HT2C RNA editing under diﬀerent
experimental conditions
Since lowering endogenous brain serotonin via a genetic
strategy did not signiﬁcantly alter 5-HT2C RNA editing,
we wondered if pharmacologic manipulations might alter
5-HT2C RNA editing. Simultaneously, we optimized our
experimental protocol to generate more sequence reads
with a lower error rate and to further reduce the cost to
measure editing in each sample. To optimize the number
Table 4. Comparison of transcripts detected using the LTS and HTS methods
WT LTS KO LTS WT HTS KO HTS
AAAAA 14.10±3.94 AAAAA 6.82±2.69 AAAAA 2.870±0.263 AAAAA 3.086±0.468
AAAAG 8.97±3.24 AAAAG 3.41±1.93 AAAAG 5.158±0.477 AAAAG 5.305±0.665
AAAGA 0.847±0.106 AAAGA 0.879±0.142
AAAGG 3.41±1.93 AAAGG 2.158±0.216 AAAGG 2.524±0.388
AAGAA 0.172±0.015 AAGAA 0.188±0.025
AAGAG 0.206±0.059 AAGAG 0.136±0.020
AAGGA 1.28±1.27 AAGGA 0.106±0.035 AAGGA 0.105±0.045
AAGGG 0.044±0.003 AAGGG 0.078±0.019
AGAAA 3.41±1.93 AGAAA 0.349±0.062 AGAAA 0.364±0.101
AGAAG 3.41±1.93 AGAAG 0.546±0.023 AGAAG 0.390±0.029
AGAGA 0.019±0.005 AGAGA 0.019±0.002
AGAGG 1.14±1.13 AGAGG 0.094±0.017 AGAGG 0.068±0.023
AGGAA 0.001±0.001 AGGAA 0.001±0.001
AGGAG 1.14±1.13 AGGAG 0.005±0.001 AGGAG 0.018±0.014
AGGGA 0.019±0.011 AGGGA 0.060±0.018
AGGGG 0.009±0.009 AGGGG 0.009±0.007
GGGAA 0.274±0.053 GGGAA 0.307±0.041
GGGAG 2.56±1.79 GGGAG 0.883±0.186 GGGAG 0.970±0.345
GGGGA 1.14±1.13 GGGGA 0.177±0.024 GGGGA 0.123±0.024
GGGGG 1.14±1.13 GGGGG 0.340±0.054 GGGGG 0.301±0.049
GGAAA 10.25±3.43 GGAAA 7.95±2.88 GGAAA 8.852±0.472 GGAAA 8.867±0.183
GGAAG 35.90±5.43 GGAAG 40.91±5.24 GGAAG 32.644±0.793 GGAAG 32.799±1.559
GGAGA 3.85±2.18 GGAGA 3.41±1.93 GGAGA 9.363±0.144 GGAGA 9.262±0.151
GGAGG 17.95±4.35 GGAGG 14.77±3.78 GGAGG 22.795±1.395 GGAGG 21.382±1.022
GAGAA 0.871±0.046 GAGAA 0.685±0.016
GAGAG 0.402±0.057 GAGAG 0.386±0.026
GAGGA 1.14±1.13 GAGGA 0.664±0.013 GAGGA 0.749±0.064
GAGGG 1.14±1.13 GAGGG 0.928±0.112 GAGGG 0.777±0.130
GAAAA 1.28±1.27 GAAAA 2.27±1.59 GAAAA 3.679±0.365 GAAAA 3.908±0.478
GAAAG 3.85±2.18 GAAAG 2.27±1.59 GAAAG 4.342±0.232 GAAAG 4.737±0.579
GAAGA 0.374±0.025 GAAGA 0.388±0.046
GAAGG 1.14±1.13 GAAGG 0.807±0.055 GAAGG 1.129±0.079
Table 3. Percentage of each transcript arising from sequencing error
Isoform Transcript % Arising from
error—Method 1
% Arising from
error—Method 2
INI AAAAA 0.19±0.01 0.06±0.01
INV AAAAG 0.10±0.01 0.03±0.01
ISI AAAGA 0.34±0.05 0.11±0.02
ISV AAAGG 0.14±0.02 0.04±0.01
IDI AAGAA 1.08±0.33 0.34±0.05
IDV AAGAG 1.81±0.83 0.65±0.08
IGI AAGGA 1.09±0.55 0.34±0.05
IGV AAGGG 2.92±0.92 0.91±0.13
MNI AGAAA 2.03±0.82 0.63±0.09
MNV AGAAG 4.51±1.08 1.40±0.20
MSI AGAGA 32.66±9.96 10.14±1.48
MSV AGAGG 19.55±9.48 6.07±0.89
MDI AGGAA 48.26±16.30 14.99±2.19
MDV AGGAG 16.12±9.47 5.01±0.73
MGI AGGGA 0.37±0.24 0.11±0.02
MGV AGGGG 13.44±12.88 4.17±0.61
VDI GGGAA 1.76±0.50 0.55±0.08
VDV GGGAG 1.82±0.58 0.57±0.08
VGI GGGGA 3.44±1.18 1.07±0.16
VGV GGGGG 3.39±0.53 1.05±0.15
VNI GGAAA 0.28±0.02 0.09±0.01
VNV GGAAG 0.06±0.01 0.02±0.01
VSI GGAGA 0.17±0.01 0.05±0.01
VSV GGAGG 0.09±0.01 0.03±0.01
VDI GAGAA 0.33±0.07 0.10±0.01
VDV GAGAG 0.88±0.14 0.27±0.04
VGI GAGGA 0.16±0.03 0.05±0.01
VGV GAGGG 0.14±0.05 0.04±0.01
VNI GAAAA 0.25±0.03 0.08±0.01
VNV GAAAG 0.51±0.09 0.16±0.02
VSI GAAGA 2.14±0.32 0.66±0.10
VSV GAAGG 1.69±0.44 0.52±0.08
e118 Nucleic Acids Research, 2010,Vol.38, No. 10 PAGE 6 OF 13of sequence reads generated, we altered the forward
primer to incorporate a sequence which allows us to use
the Illumina-optimized sequencing primer. To further
reduce costs, we incorporated a sample identiﬁcation tag
in the forward primer, using a diﬀerent forward primer/
identiﬁcation tag for each sample. As a result, we were
able to multiplex 26 samples in one lane, reducing the
cost of processing one sample by approximately a factor
of 26. It should be noted that this experimental design
necessitates a longer read length (76bp). With these mod-
iﬁcations, we generated 71187995 reads after ﬁltering
(Figure 1). We also calculated new transcript frequency
thresholds for the multiplexed sequencing protocol.
Notably, these new thresholds were considerably lower
than in the original protocol (none >15%, and all but
two of the rest <5%).
We proceeded to examine the eﬀect of a variety of
chronic treatment regimens. These included chronic
agonist [LSD, 0.25mg/kg (31); DOI, 1mg/kg (32);
MK-212, 5mg/kg (33)], inverse agonist [SB206553, 5mg/
kg (34,35)], antimanic [lithium 200mg/kg (36,37);
valproate, 300mg/kg (36,38,39)], antipsychotic [clozapine,
10mg/kg (40); olanzapine 5mg/kg (41–43)] and
antidepressant [ﬂuoxetine, 10mg/kg (41,44–46);
amitriptyline, 10mg/kg (47)]. First, we treated C57BL/6
mice daily with saline, ﬂuoxetine, amitriptyline or
olanzapine for a 28-day period, the rationale being that
ﬂuoxetine is a selective serotonin reuptake inhibitor
(SSRI), which should raise endogenous brain serotonin
levels, and amitriptyline is a tricyclic antidepressant
which also inhibits serotonin reuptake. Olanzapine is an
atypical antipsychotic drug, which is also a non-selective
5-HT2C antagonist that would be predicted to have no
eﬀect on 5-HT2C editing based on our aforementioned
Pet-1 results. We proceeded to measure the editing fre-
quency at the A, B, C, D and E sites in three brain
regions: striatum, hippocampus and cortex.
Antidepressant eﬀects are thought to involve changes in
hippocampal function, and a previous study has examined
the eﬀect of ﬂuoxetine on cortical 5-HT2C RNA editing
(21). We examined striatal editing because 5-HT2C recep-
tors are known to be highly expressed in this region
(28,48,49). Interestingly, we found that ﬂuoxetine-treated
mice exhibited an increase in A and B site editing relative
to their saline-treated littermates, with no change in C, D
or E site editing in striatum and hippocampus, but not
Figure 2. (A) Comparison of editing frequencies by site as measured by LTS and HTS. The LTS and HTS approaches produce comparable estimates
of editing frequencies by site. Two-way ANOVA analysis (HTS P-value=0.4369; LTS P-value=0.0812) and Bonferroni post-tests indicate that
there is no eﬀect of genotype on site editing frequency. (B) Comparison of common transcript frequencies as measured by LTS and HTS. Estimates
derived by LTS and HTS are comparable. Two-way ANOVA analysis (HTS P-value=0.9976; LTS P-value=0.4011) and Bonferroni post-tests
comparing common transcripts detected in both genotypes with both methods show no signiﬁcant eﬀect of genotype on transcript frequency
diﬀerences. (C) Comparison of rare transcript frequencies as measured by LTS and HTS. No rare transcript is detected in both genotypes by
LTS, so statistical comparison between genotypes is not possible. HTS, on the other hand, permits more sensitive estimation of rare transcript
frequencies. Two-way ANOVA analysis (P-value=0.9867) and Bonferroni post-tests of the HTS-generated rare transcript data shows that genotype
has no signiﬁcant eﬀect on transcript frequency. LTS: N=78 wild-types, N=88 knockouts; HTS: N=3 littermate pairs, 8647465 sequences total.
Transcript frequencies are presented as means, expressed as a percentage of the total population of transcripts, ±SEM.
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hand, led to an increase in A and B site editing only in
hippocampus. Olanzapine had no signiﬁcant eﬀect on
5-HT2C editing.
To further characterize our results, we examined
whether our overall editing frequencies calculated at
each site were consistent with ﬁndings at the transcript
level. We reasoned that an increase in A and B site
editing should lead to a decrease in transcripts that are
unmodiﬁed at both sites (AA***), with a concomitant
increase in deaminated transcripts (AG***, GA***, and/
or GG***). As seen in Figure 3A–C, while AA***
Figure 3. (A–C) Column 1—comparison of editing frequencies by site after treatment with saline or drug daily for 28 days, in striatum, hippocampus
and cortex. Two-way ANOVA analysis (P<0.0001) and Bonferroni post-tests for pair-wise comparisons indicates that chronic ﬂuoxetine and
amitriptyline treatment leads to an increase in the proportion of transcripts edited at the A and B sites in striatum (ﬂuoxetine) and hippocampus
(ﬂuoxetine and amitriptyline), with no eﬀect on other sites. Column 2—comparison of transcript frequencies by transcript group after treatment with
saline or ﬂuoxetine daily for 28 days in striatum, hippocampus, and cortex. Two-way ANOVA analysis (P<0.0001) and Bonferroni post-tests for
pair-wise comparisons indicates that ﬂuoxetine (striatum and hippocampus) and amitriptyline (hippocampus) treatment lead to a decrease in the
proportion of transcripts unedited at both the A and B sites (AA***), an increase in the proportion of transcripts edited at both the A and B sites
(GG***), and no change in transcripts edited at either the A or B site (AG*** and GA***). N=4 for each treatment regimen, with the estimates for
each sample obtained by analyzing an average of 431442 sequences. Editing frequencies and transcript frequencies are presented as means, expressed
as a percentage of the total population of transcripts, ±SEM. *P<0.05; **P<0.01; ***P<0.001.
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AG*** and GA*** remain unchanged. Thus, ﬂuoxetine
and amitriptyline increase the editing frequencies at the A
and B sites by increasing the simultaneous editing of those
two sites, most likely by regulating ADAR1 activity.
Furthermore, the increase in A and B site editing
resulted in signiﬁcant changes at the transcript level in
either two or three out of 32 transcripts after ﬂuoxetine
treatment (Striatum: AAAAA-INI, Saline—7.85%>
Fluoxetine—5.70%, P<0.01; AAAAG-INV, Saline—
8.83%>Fluoxetine—5.35%, P<0.001; GGAAG-VNV,
SALINE—32.50%<Fluoxetine—35.42%, P<0.001;
Hippocampus: AAAAG-INV, Saline—17.84%>
Fluoxetine—12.22%, P<0.001; GGAAG-VNV,
Saline—27.17%<Fluoxetine—31.57%, P<0.001) and
four of 32 transcripts after amitriptyline treatment
(Hippocampus: AAAAA-INI, Saline—10.59%>
Amitriptyline—6.94%, P<0.05; AAAAG-INV,
Saline—17.84%>Amitriptyline—8.36%, P<0.001; GG
AAG-VNV, Saline—27.17%<Amitriptyline—35.21%,
P<0.001; GGAGG-VSV, Saline—13.59%<
Amitriptyline—17.26%, P<0.05). There were no signiﬁ-
cant changes in any of the other 28 transcripts after
chronic ﬂuoxetine or amitriptyline treatment, and no sig-
niﬁcant changes whatsoever after olanzapine treatment.
We next examined several other drugs which can
directly (e.g. LSD, DOI, SB206553, MK-212, clozapine)
or indirectly (e.g. lithium, valproate) modulate 5-HT2C
signaling. The treatment regimens were 10-day saline,
LSD and DOI; and 14-day saline, SB206553, MK-212,
clozapine, lithium and valproate. SB206553, a relatively
selective 5-HT2C inverse agonist, caused a small but sig-
niﬁcant increase in 5-HT2C editing at the A and B sites in
striatum only (Figure 4A), decreasing the proportion of
AA*** transcripts and increasing the proportion of
GG*** transcripts as expected. Lithium, which does not
act directly at 5-HT2C receptors, but which can alter
5-HT2C signaling (50), increased editing at the C and D
sites, which are edited by ADAR2, in cortex only,
resulting in the expected changes in the proportions of
***AA and ***GG transcripts (Figure 4B). LSD, DOI,
MK-212, clozapine and valproate did not alter 5-HT2C
editing in any of the brain regions examined (Table 5).
DISCUSSION
In this article, we developed and utilized an ultra HTS
approach using the Illumina Genome Analyzer II
platform to analyze 5-HT2C RNA editing and provide
quantitative estimates of editing site frequencies and tran-
script/isoform frequencies. We also compared our ultra
high-throughput approach to the most commonly
used low-throughput approach and show that our
high-throughput approach is superior in part because
it detects all transcripts, facilitating between-genotype
comparisons of even rare transcripts, which is either
impossible or prohibitively expensive and laborious by
the more common low-throughput approach. We then
used our novel approach to assess the eﬀect of endogenous
serotonin on RNA editing of the 5-HT2C receptor by
comparing RNA editing frequencies in the hippocampi
of Pet-1 wild-type and knockout mice, which have a defec-
tive serotonin system due to dysfunctional serotonergic
raphe neurons that produce almost no serotonin.
Surprisingly, we found that abnormally low levels of
brain serotonin had no signiﬁcant eﬀect on 5-HT2C
receptor RNA editing. We also show that the editing
frequencies at each of the ﬁve individual editing sites are
unchanged and that there is little or no alteration in the
frequency of any one of the 32 5-HT2C transcripts in the
absence of a normally functioning central serotonergic
system. An examination of the eﬀect on 5-HT2C editing
of 10 diﬀerent drugs with varying mechanisms of action
indicated that their ability to modulate editing could not
be predicted in a straightforward manner based on their
activity at 5-HT2C receptors. Notably, our results in
untreated mice are consistent with previous studies mea-
suring the proportions of transcripts edited at the ﬁve
edited sites (21,24).
Prior studies have yielded inconsistent results regarding
the eﬀects of various pharmacological manipulations of
the serotonergic system on 5-HT2C RNA editing. As an
example, one study reported increases in editing
frequencies at the A, B, C and D sites after ﬂuoxetine
treatment of BALB/c mice, and no RNA editing
changes after ﬂuoxetine treatment in C57BL/6 mice
(though there were consistent trends towards a decrease
at the A, B, C and D sites). It should be noted that these
mice were subjected to a modiﬁed forced swim test (FST)
on their last 2 days of treatment (51). Another study in
rats reported decreases in A, B and E site editing
frequencies after ﬂuoxetine treatment (52).
A potential shortcoming of all of these previous studies
is the small number of sequences that was sampled, typi-
cally 50 or so samples per animal, with three or four
animals in each treatment group. Small sample sizes are
inevitable due to the labor-intensive nature of methods
that rely on sequencing transcripts derived from individual
bacterial clones (one clone=one transcript). The small
sample sizes make measuring editing at the E site diﬃcult
because of the very low frequency of editing at this site
(<5%). Not surprisingly, therefore, the most common
change reported between treatment groups is at the
E site, which is the most diﬃcult to measure accurately.
Furthermore, previous studies generally focus only on
common transcripts, because rare transcripts are impossi-
ble to identify and quantify given the small sample sizes.
Other studies rely on primer-extension analysis, which
does not allow for the comprehensive assessment of
individual transcript frequencies, but merely editing
frequencies at each site. Two very recent articles apply
next-generation sequencing technology to measuring or
discovering RNA editing (53,54). Both sequenced only a
few hundred to a few thousand 5-HT2C transcripts—an
approach comparable to what can be done with presently
established methods. In addition, neither study examined
all 32 conceivable transcripts and no comparison was
made with a gold standard method to validate the results.
Our novel HTS method has a number of advantages
with respect to the previously established methods for
quantifying RNA editing. First, HTS is many orders of
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Genome Analyzer II, on which our HTS experiment was
performed, is amenable to multiplexing 26 or more
samples in each lane of a ﬂow cell, which cuts the cost
per experiment by an order of magnitude, making RNA
editing analysis by HTS considerably less expensive on a
per animal basis than RNA editing analysis by LTS.
Second, measuring RNA editing by HTS is less
labor-intensive than LTS. For HTS, PCR fragments are
simply generated and loaded into the Cluster Station and
then the Genome Analyzer II, which sequences individual
fragments directly. To generate similar information
by LTS, fragments must be ﬁrst ligated into a vector,
the vector transformed into bacteria, the bacteria plated,
individual bacterial clones picked and grown, plasmids
Figure 4. (A) Comparison of editing frequencies by site after treatment with saline or drug daily for 14 days, in striatum. Two-way ANOVA analysis
(P<0.0001) and Bonferroni post-tests for pair-wise comparisons indicates that chronic SB206553 (14 D) treatment leads to an increase in the
proportion of transcripts edited at the A and B sites in striatum, with no eﬀect on other sites. Comparison of transcript frequencies by transcript
group after treatment with saline or SB206553 daily for 14 days in striatum, hippocampus and cortex is consistent with the increase in A and B site
editing. Two-way ANOVA analysis (P<0.0001) and Bonferroni post-tests for pair-wise comparisons indicates that SB206553 treatment leads to a
decrease in the proportion of transcripts unedited at both the A and B sites (AA***), an increase in the proportion of transcripts edited at both the A
and B sites (GG***), and no change in transcripts edited at either the A or B site (AG*** and GA***). (B) Comparison of editing frequencies by site
after treatment with saline or drug daily for 14 days in cortex. Two-way ANOVA analysis (P<0.0001) and Bonferroni post-tests for pair-wise
comparisons indicates that chronic lithium treatment leads to an increase in the proportion of transcripts edited at the C and D sites in striatum, with
no eﬀect on other sites. Comparison of transcript frequencies by transcript group after treatment with saline or lithium daily for 14 days in cortex is
consistent with the increase in C and D site editing. Two-way ANOVA analysis (P<0.0001) and Bonferroni post-tests for pair-wise comparisons
indicates that lithium treatment leads to a decrease in the proportion of transcripts unedited at both the C and D sites (***AA), an increase in the
proportion of transcripts edited at both the C and D sites (***GG), and no change in transcripts edited at either the C or D site (***AG and
***GA). N=4 for each treatment regimen, with the estimates for each sample obtained by analyzing an average of 431442 sequences. Editing
frequencies and transcript frequencies are presented as means, expressed as a percentage of the total population of transcripts, ±SEM. *P<0.05;
**P<0.01; ***P<0.001.
Table 5. Summary of ﬁndings from multiplexed experiment
Drug Treatment
length
Striatum Hippocampus Cortex
Fluoxetine 28 D * * NS
Amitriptyline 28 D NS * NS
Olanzapine 28 D NS NS NS
SB206553 14 D * NS NS
Lithium 14 D NS NS *
Clozapine 14 D NS NS NS
MK-212 14 D NS NS NS
Valproate 14 D NS NS NS
LSD 10 D NS NS NS
DOI 10 D NS NS NS
*The treatment regimen signiﬁcantly altered editing.
NS, no signiﬁcant eﬀect of the treatment regimen on editing.
e118 Nucleic Acids Research, 2010,Vol.38, No. 10 PAGE 10 OF 13puriﬁed, and ﬁnally the inserted fragment sequenced by
Sanger sequencing. Third, HTS is advantageous as
compared to primer-extension analysis and other similar
PCR-based strategies in that data is digital rather than
analog, with at least some of the advantages associated
with digital information (55). Fourth, HTS permits the
analysis of rare transcripts, which is either impossible or
prohibitively expensive and labor intensive by the LTS
method. The analysis of rare transcripts is also impossible
by analog methods such as primer-extension analysis. We
have also compared our results, where possible, to gold
standard LTS, thus validating our method and the
sequence quality ﬁlters we used.
To our knowledge, this study represents the ﬁrst com-
prehensive measurement of the frequencies of all
32 possible 5-HT2C transcripts. Although we detected
many rare transcripts, it is not clear to what extent rare
transcripts may or may not be important in vivo.
Experiments with mice expressing only the fully edited
VGV isoform, however, have indicated that mutant
VGV mice exhibit increases in total 5-HT2C expression
as compared to wild-type mice, along with dramatic
reductions in fat mass despite hyperphagia (18).
This suggests the possibility that alterations in rare tran-
script frequencies may have important physiological
consequences.
Finally, we would like to note that our data are easily
reconcilable with the known mechanisms by which the
5-HT2C receptor pre-mRNA is edited by ADAR1, which
edits the A and B sites, and ADAR2, which edits the C
and D sites (16). Our data suggest that ﬂuoxetine/
amitriptyline and SB206553, which have the opposite
eﬀects on signaling through the 5-HT2C receptor but none-
theless all increase editing frequency at the A and B sites in
at least one brain region, modulate 5-HT2C RNA editing
by inﬂuencing ADAR1 function at the receptor without
aﬀecting function of ADAR2. In contrast, lithium appears
to aﬀect only the ability of ADAR2 to edit 5-HT2C
pre-mRNA. Furthermore, our data indicate that chronic
treatment leads to reciprocal changes in transcripts that
are either unedited or fully edited at the A and B or C
and D sites, with no change in transcripts edited at only
one or the other site. We also show region-speciﬁc changes
with respect to the handful of drugs which do aﬀect
editing (ﬂuoxetine, amitriptyline, SB206553 and lithium)
Finally, although we report signiﬁcant changes in editing
after some drug regimens, most of these changes are rela-
tively small in magnitude (typically <10%) and it is
unclear if such small changes are physiologically
signiﬁcant.
In summary, we have developed and optimized a novel
ultra high-throughput method for measuring RNA editing
digitally by adapting newly developed genome-wide
sequencing tools. Our method is inexpensive, technically
feasible for most laboratories, and provides more compre-
hensive information regarding 5-HT2C receptor editing
than either existing analog methods or digital low-
throughput methods. We applied our newly developed
ultra high-throughput method to assess whether or not
modulating endogenous brain serotonin would alter
5-HT2C RNA editing. We demonstrated through our
more powerful measurement method that lowering
endogenous brain serotonin levels does not aﬀect
5-HT2C RNA editing in vivo. In contrast, treating mice
with chronic ﬂuoxetine, amitriptyline, SB206553 and
lithium increased editing at a subset of the sites in one
more brain regions, whereas chronic LSD, DOI,
MK-212, valproate, clozapine and olanzapine had no
eﬀect. Our data suggest that the ability of a drug to
alter 5-HT2C RNA editing cannot be predicted from its
activity at 5-HT2C receptors. Given its considerable
advantages, massively parallel HTS is likely to rapidly
become the method of choice for quantifying RNA
editing as next-generation sequencing platforms become
more widely available.
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